Industry Insights - The sales data for April in the Chinese construction machinery industry shows mixed results, with non-earthmoving machinery sales fluctuating. Forklift sales remain resilient, while tower crane domestic sales have decreased by 61% year-on-year, and exports increased by 49%. Aerial work platform sales have dropped by 31% year-on-year, indicating ongoing weakness. The report maintains a positive outlook on earthmoving machinery due to its early recovery in project and replacement cycles [2][4]. - The report continues to favor Sany Heavy Industry (600031 CH, Buy) and Hengli Hydraulic (601100 CH, Buy) due to their high revenue share from excavators. It also supports Zoomlion (1157 HK / 000157 CH, Buy) for its strategy of rapid expansion in emerging markets through a broad product line. Conversely, a cautious view is maintained on Zhejiang Dingli (603338 CH, Hold) due to uncertainties surrounding U.S. tariff policies [2][4]. Company Analysis - Trip.com Group (TCOM US, Buy, Target Price: $70.00) reported Q1 2025 revenue of RMB 13.9 billion, a 16% year-on-year increase, aligning with expectations. Non-GAAP operating profit reached RMB 4 billion, exceeding forecasts by 7%, driven by optimized sales and marketing expenses. The overall travel demand remains resilient, and the company's international expansion is progressing as planned, expected to yield long-term value [5]. - Bilibili (BILI US, Buy, Target Price: $26.50) announced Q1 2025 revenue growth of 24% to RMB 7 billion, meeting market expectations. Adjusted net profit reached RMB 362 million, a significant improvement from a net loss of RMB 456 million in the previous year, driven by an 8% increase in gross margin and a 13% reduction in R&D expenses. The company is projected to maintain a 20% year-on-year revenue growth in Q2 2025, with further profit margin improvements anticipated [5]. - Three-Sixty Biopharmaceuticals (1530 HK, Buy, Target Price: HKD 28.32) has licensed its PD-1/VEGF candidate to Pfizer, receiving an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion, along with a double-digit sales share. This deal exceeds market expectations and is expected to significantly enhance the company's profits in 2025 [6][8].
招银国际每日投资策略-20250521
Zhao Yin Guo Ji·2025-05-21 04:14